PSI-6130 is the (beta-D)-isomer; has antiviral activity against hepatitis C virus; structure in first source
Also Known As:
PSI 6130; PSI-6130; PSI6130
Networked: 2 relevant articles (0 outcomes, 0 trials/studies)

Bio-Agent Context: Research Results


1. Symons, Julian: 1 article (12/2008)
2. Jiang, Wen-Rong: 1 article (12/2008)
3. Alker, Andre: 1 article (12/2008)
4. Leveque, Vincent: 1 article (12/2008)
5. Najera, Isabel: 1 article (12/2008)
6. Ma, Han: 1 article (12/2008)
7. Cammack, Nick: 1 article (12/2008)
8. Inocencio, Nicole: 1 article (12/2008)
9. Philipp, Friederike: 1 article (12/2008)
10. Le Pogam, Sophie: 1 article (12/2008)

Related Diseases

1. Infection
12/01/2008 - "In conclusion, PSI-6130 presents a high barrier to resistance selection in vitro, selects for variants exhibiting only low-level resistance, and lacks cross-resistance with R1479, supporting the continued development of the prodrug R7128 as a therapeutic agent for the treatment of HCV infection."
09/01/2008 - "Foremost among the newly described antiviral agents that may be developed into drugs are, for the treatment of human papilloma virus (HPV) infections, cPrPMEDAP; for the treatment of herpes simplex virus (HSV) infections, BAY 57-1293; for the treatment of varicella-zoster virus (VZV) infections, FV-100 (prodrug of Cf 1743); for the treatment of cytomegalovirus (CMV) infections, maribavir; for the treatment of poxvirus infections, ST-246; for the treatment of hepatitis B virus (HBV) infections, tenofovir disoproxil fumarate (TDF) (which in the meantime has already been approved in the EU); for the treatment of various DNA virus infections, the hexadecyloxypropyl (HDP) and octadecyloxyethyl (ODE) prodrugs of cidofovir; for the treatment of orthomyxovirus infections (i.e., influenza), peramivir; for the treatment of hepacivirus infections (i.e., hepatitis C), the protease inhibitors telaprevir and boceprevir, the nucleoside RNA replicase inhibitors (NRRIs) PSI-6130 and R1479, and various non-nucleoside RNA replicase inhibitors (NNRRIs); for the treatment of human immunodeficiency virus (HIV) infections, integrase inhibitors (INIs) such as elvitegravir, nucleoside reverse transcriptase inhibitors (NRTIs) such as apricitabine, non-nucleoside reverse transcriptase inhibitors (NNRTIs) such as rilpivirine and dapivirine; and for the treatment of both HCV and HIV infections, cyclosporin A derivatives such as the non-immunosuppressive Debio-025."
2. HIV Infections (HIV Infection)
3. Poxviridae Infections
4. Papilloma (Papillomatosis)
5. Orthomyxoviridae Infections

Related Drugs and Biologics

1. 4'-azidocytidine
2. Integrase Inhibitors
3. Reverse Transcriptase Inhibitors
4. Cyclosporine (Ciclosporin)
5. RNA Replicase (RNA Dependent RNA Polymerase)
6. Protease Inhibitors (Protease Inhibitor)
7. Prodrugs
8. Antiviral Agents (Antivirals)
9. FV-100
10. N- (3- amino- 1- (cyclobutylmethyl)- 2,3- dioxopropyl)- 3- (2- ((((1,1- dimethylethyl)amino)carbonyl)amino)- 3,3- dimethyl- 1- oxobutyl)- 6,6- dimethyl- 3- azabicyclo(3.1.0)hexan- 2- carboxamide